Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy
Glioblastoma multiforme is the most frequent and most malignant primary brain tumor with poor prognosis despite surgical removal and radio-chemotherapy. In this setting, immunotherapeutical strategies have great potential, but the reported repertoire of tumor associated antigens is only for HLA-A*02...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2013
|
| In: |
Journal of neuro-oncology
Year: 2013, Volume: 111, Issue: 3, Pages: 285-294 |
| ISSN: | 1573-7373 |
| DOI: | 10.1007/s11060-012-1028-8 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s11060-012-1028-8
|
| Author Notes: | Marian Christoph Neidert, Oliver Schoor, Claudia Trautwein, Nico Trautwein, Lisa Christ, Arthur Melms, Jürgen Honegger, Hans-Georg Rammensee, Christel Herold-Mende, Pierre-Yves Dietrich, Stefan Stevanović |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1780193033 | ||
| 003 | DE-627 | ||
| 005 | 20220820085444.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211203s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11060-012-1028-8 |2 doi | |
| 035 | |a (DE-627)1780193033 | ||
| 035 | |a (DE-599)KXP1780193033 | ||
| 035 | |a (OCoLC)1341434602 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Neidert, Marian Christoph |d 1984- |e VerfasserIn |0 (DE-588)1055008691 |0 (DE-627)792487664 |0 (DE-576)411069446 |4 aut | |
| 245 | 1 | 0 | |a Natural HLA class I ligands from glioblastoma |b extending the options for immunotherapy |c Marian Christoph Neidert, Oliver Schoor, Claudia Trautwein, Nico Trautwein, Lisa Christ, Arthur Melms, Jürgen Honegger, Hans-Georg Rammensee, Christel Herold-Mende, Pierre-Yves Dietrich, Stefan Stevanović |
| 264 | 1 | |c 2013 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online: 23 December 2012 | ||
| 500 | |a Gesehen am 08.12.2021 | ||
| 520 | |a Glioblastoma multiforme is the most frequent and most malignant primary brain tumor with poor prognosis despite surgical removal and radio-chemotherapy. In this setting, immunotherapeutical strategies have great potential, but the reported repertoire of tumor associated antigens is only for HLA-A*02 positive tumors. We describe the first analysis of HLA-peptide presentation patterns in HLA-A*02 negative glioma tissue combined with gene expression profiling of the tumor samples by oligonucleotide microarrays. We identified numerous candidate peptides for immunotherapy. These are peptides derived from proteins with a well-described role in glioma tumor biology and suitable gene expression profiles such as PTPRZ1, EGFR, SEC61G and TNC. Information obtained from complementary analyses of HLA-A*02 negative tumors not only contributes to the discovery of novel shared glioma antigens, but most importantly provides the opportunity to tailor a patient-individual cocktail of tumor-associated peptides for a personalized, targeted immunotherapeutic approach in HLA-A*02 negative patients. | ||
| 700 | 1 | |a Schoor, Oliver |e VerfasserIn |4 aut | |
| 700 | 1 | |a Trautwein, Claudia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Trautwein, Nico |e VerfasserIn |4 aut | |
| 700 | 1 | |a Christ, Lisa |e VerfasserIn |4 aut | |
| 700 | 1 | |a Melms, Arthur |e VerfasserIn |4 aut | |
| 700 | 1 | |a Honegger, Jürgen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rammensee, Hans-Georg |e VerfasserIn |4 aut | |
| 700 | 1 | |a Herold-Mende, Christel |e VerfasserIn |0 (DE-588)1022936549 |0 (DE-627)717335577 |0 (DE-576)366194267 |4 aut | |
| 700 | 1 | |a Dietrich, Pierre-Yves |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stevanović, Stefan |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of neuro-oncology |d Dordrecht [u.a.] : Springer Science + Business Media B.V, 1983 |g 111(2013), 3, Seite 285-294 |h Online-Ressource |w (DE-627)32046122X |w (DE-600)2007293-4 |w (DE-576)107058944 |x 1573-7373 |7 nnas |a Natural HLA class I ligands from glioblastoma extending the options for immunotherapy |
| 773 | 1 | 8 | |g volume:111 |g year:2013 |g number:3 |g pages:285-294 |g extent:10 |a Natural HLA class I ligands from glioblastoma extending the options for immunotherapy |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s11060-012-1028-8 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20211203 | ||
| 993 | |a Article | ||
| 994 | |a 2013 | ||
| 998 | |g 1022936549 |a Herold-Mende, Christel |m 1022936549:Herold-Mende, Christel |d 910000 |d 911200 |d 50000 |e 910000PH1022936549 |e 911200PH1022936549 |e 50000PH1022936549 |k 0/910000/ |k 1/910000/911200/ |k 0/50000/ |p 9 | ||
| 999 | |a KXP-PPN1780193033 |e 4013464543 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1780193033","id":{"doi":["10.1007/s11060-012-1028-8"],"eki":["1780193033"]},"origin":[{"dateIssuedKey":"2013","dateIssuedDisp":"2013"}],"person":[{"given":"Marian Christoph","role":"aut","family":"Neidert","display":"Neidert, Marian Christoph"},{"display":"Schoor, Oliver","given":"Oliver","family":"Schoor","role":"aut"},{"family":"Trautwein","role":"aut","given":"Claudia","display":"Trautwein, Claudia"},{"given":"Nico","role":"aut","family":"Trautwein","display":"Trautwein, Nico"},{"display":"Christ, Lisa","given":"Lisa","role":"aut","family":"Christ"},{"given":"Arthur","family":"Melms","role":"aut","display":"Melms, Arthur"},{"display":"Honegger, Jürgen","family":"Honegger","role":"aut","given":"Jürgen"},{"display":"Rammensee, Hans-Georg","given":"Hans-Georg","role":"aut","family":"Rammensee"},{"given":"Christel","role":"aut","family":"Herold-Mende","display":"Herold-Mende, Christel"},{"display":"Dietrich, Pierre-Yves","given":"Pierre-Yves","role":"aut","family":"Dietrich"},{"role":"aut","family":"Stevanović","given":"Stefan","display":"Stevanović, Stefan"}],"language":["eng"],"relHost":[{"part":{"extent":"10","pages":"285-294","year":"2013","issue":"3","text":"111(2013), 3, Seite 285-294","volume":"111"},"pubHistory":["1.1983 -"],"origin":[{"dateIssuedKey":"1983","publisherPlace":"Dordrecht [u.a.] ; Dordrecht [u.a.]","dateIssuedDisp":"1983-","publisher":"Springer Science + Business Media B.V ; Kluwer"}],"language":["eng"],"id":{"zdb":["2007293-4"],"eki":["32046122X"],"issn":["1573-7373"]},"recId":"32046122X","note":["Gesehen am 11.06.2018","Fortsetzung der Druck-Ausgabe"],"title":[{"title":"Journal of neuro-oncology","title_sort":"Journal of neuro-oncology"}],"physDesc":[{"extent":"Online-Ressource"}],"disp":"Natural HLA class I ligands from glioblastoma extending the options for immunotherapyJournal of neuro-oncology","type":{"media":"Online-Ressource","bibl":"periodical"}}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"name":{"displayForm":["Marian Christoph Neidert, Oliver Schoor, Claudia Trautwein, Nico Trautwein, Lisa Christ, Arthur Melms, Jürgen Honegger, Hans-Georg Rammensee, Christel Herold-Mende, Pierre-Yves Dietrich, Stefan Stevanović"]},"physDesc":[{"extent":"10 S."}],"title":[{"title_sort":"Natural HLA class I ligands from glioblastoma","subtitle":"extending the options for immunotherapy","title":"Natural HLA class I ligands from glioblastoma"}],"note":["Published online: 23 December 2012","Gesehen am 08.12.2021"]} | ||
| SRT | |a NEIDERTMARNATURALHLA2013 | ||